CliffBio
small molecule

OXYBUTYNIN CHLORIDE

OXYBUTYNIN CHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyOsmotica Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameOXYBUTYNIN CHLORIDE
Active ingredientOXYBUTYNIN CHLORIDE
Strength15MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2009
Marketing statusRX

More from Osmotica Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OXYBUTYNIN CHLORIDE patent cliff — loss of exclusivity — | CliffBio